Philips upgrades oncology platform for RT planning

According to John Henson, MD, patients with ovarian, breast, endometrial, and colon cancers benefit the most from proactive hereditary analyses.

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

Researchers have demonstrated that a tandem CAR T cell targeting mesothelin and MUC16 ectodomain is able to outmaneuver tumor heterogeneity, outperforming single target CAR T cells in mixed ovarian and pancreatic models.

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

No dose-limiting toxicities were observed among 12 patients with advanced EGFR-mutated NSCLC treated with quaratusugene ozeplasmid and osimertinib.

Subgroup data from the ARASENS trial support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC regardless of age.